130 related articles for article (PubMed ID: 6492486)
21. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Lyoo CH; Ryu YH; Lee MJ; Lee MS
Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
[TBL] [Abstract][Full Text] [Related]
22. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
23. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
24. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
Saarinen A; Myllylä VV; Tokola O; Hokkanen E
Acta Neurol Scand; 1978 Dec; 58(6):340-9. PubMed ID: 369277
[TBL] [Abstract][Full Text] [Related]
25. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
26. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
27. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
[TBL] [Abstract][Full Text] [Related]
28. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
29. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
30. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
[TBL] [Abstract][Full Text] [Related]
31. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
[TBL] [Abstract][Full Text] [Related]
32. Levodopa with benserazide or carbidopa in Parkinson disease.
Rinne UK; Mölsä P
Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
[TBL] [Abstract][Full Text] [Related]
33. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Liashchenko EA; Skripkina NA; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
[TBL] [Abstract][Full Text] [Related]
34. Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
Ogawa N; Tanaka K; Asanuma M
Neurochem Res; 2000 Jun; 25(6):755-8. PubMed ID: 10943992
[TBL] [Abstract][Full Text] [Related]
35. Effects of statins on dopamine loss and prognosis in Parkinson's disease.
Jeong SH; Lee HS; Chung SJ; Yoo HS; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
Brain; 2021 Nov; 144(10):3191-3200. PubMed ID: 34347020
[TBL] [Abstract][Full Text] [Related]
36. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
[TBL] [Abstract][Full Text] [Related]
37. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
[TBL] [Abstract][Full Text] [Related]
38. Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Simonson W; Hauser RA; Schapira AH
Ann Pharmacother; 2007 Nov; 41(11):1842-9. PubMed ID: 17878397
[TBL] [Abstract][Full Text] [Related]
39. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
40. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
